Efficacy and safety of ponatinib in patients with advanced chronic myeloid leukaemia with T315I mutation and relapsed/refractory Philadelphia chromosome positive acute lymphoblastic leukaemia.

Trial Profile

Efficacy and safety of ponatinib in patients with advanced chronic myeloid leukaemia with T315I mutation and relapsed/refractory Philadelphia chromosome positive acute lymphoblastic leukaemia.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Jun 2014

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top